Procurement specifications for Mupirocin Calcium Pharma Grade API intended for tablet, capsule, granule, and injectable process development are issued around three principal controls: salt stoichiometry, residual solvent profile, and particle-size distribution. The material is the calcium dihydrate of pseudomonic acid A, a fermentation-derived antibiotic produced by selected strains of Pseudomonas fluorescens. After chromatographic purification and salt formation, the product is dried under controlled humidity to preserve the dihydrate lattice; the theoretical water content of this lattice is 3.3% w/w. In a production-scale vacuum tray dryer, batch-to-batch water spread of 0.4% w/w to 0.8% w/w above the release target occurs when final water is inferred from jacket temperature alone. Online chamber relative humidity or outlet dew point sensing reduces this variability because the dehydration of the calcium dihydrate is governed by chamber vapor pressure rather than product temperature alone. Manufacturer model designations for this calcium dihydrate commonly distinguish an injectable micronized grade, a solid oral grade, and a non-sterile grade by Dv90 and bioburden. Laser diffraction analysis under ISO 13320:2020 is used to set the particle-size acceptance range. A solid oral granule lot is typically controlled to a Dv90 of ≤ 150 µm; an injectable suspension lot is milled to a Dv90 of ≤ 25 µm. Apparent bulk density before milling is commonly 0.30 g/cm³ to 0.50 g/cm³. Micronized calcium dihydrate is cohesive and generally does not meet direct compression flow requirements unless the particle size is enlarged by wet or dry granulation. Powder flow is evaluated by USP <1174>; a Hausner ratio above 1.35 is typical for the unmilled micronized powder and flags the need for granulation before tableting.

When injectable-grade processing must address endotoxin load and subvisible particulate burden

For injectable use, the API is not simply a sterile version of the solid oral grade. The calcium dihydrate is poorly water soluble and cannot be sterilized by terminal filtration as a solution. Micronization is performed in an ISO 14644-1 Class 8 buffer zone, and aseptic filling is conducted in an ISO 14644-1 Class 7 fill zone. Bacterial endotoxin testing by USP <85> is required. A common injectable-grade release criterion is ≤ 0.25 EU/mg, but the final limit must be derived from the maximum intended daily dose and the applicable body weight-adjusted endotoxin limit. Subvisible particulate matter is assessed by USP <788>; a reconstituted suspension intended for injection is generally targeted to meet large-volume parenteral criteria of ≤ 12 particles per container at ≥ 10 µm and ≤ 2 particles per container at ≥ 25 µm. Published clinical data for systemic oral or injectable mupirocin calcium is limited; the established regulatory history is concentrated in topical and intranasal ointments. Therefore, the injectable grade is supplied as a development-grade API only, and process validation must include active-moiety recovery after any planned sterilization step because dry heat can dehydrate the calcium dihydrate lattice. Residual solvent control follows USP <467> and ICH Q3C. For Class 3 solvents used during isolation, such as ethanol and ethyl acetate, individual residual levels are commonly restricted to ≤ 5000 ppm. Elemental impurity control follows USP <232>, USP <233>, and ICH Q3D, with limits selected according to the intended route of administration. For a non-sterile oral tablet or capsule grade, microbial enumeration by USP <61> and USP <62> typically requires total aerobic microbial count ≤ 100 CFU/g and total combined yeasts and moulds count ≤ 10 CFU/g. When the material is declared for injection, sterility testing by USP <71> becomes mandatory, and the lower bioburden specification before terminal processing is normally set at ≤ 10 CFU/g to control endotoxin introduction.

Does the calcium dihydrate offer a practical processing advantage over the free acid in granule and tablet manufacture?

Mupirocin calcium is a high-molecular-mass calcium salt in which each calcium ion is associated with two pseudomonic acid A carboxylate units. The resulting active-moiety mass fraction is 0.932 when mupirocin free acid is used as the reference: two free acid molecules of 500.6 g/mol contribute 1001.2 g/mol to a calcium dihydrate of 1074.3 g/mol. This correction factor is critical in capsule and tablet assay calculations because a formula expressed as 100.0% mupirocin calcium on the label is not equivalent to 100.0% mupirocin free acid. Pharmacopeial monographs for Mupirocin Calcium specify HPLC assay with the result stated on the dried basis, and an additional conversion to the free acid moiety is applied when clinical dosing is expressed by free acid content. The difference is not nominal: it alters the fill weight of a hard gelatin capsule by approximately 7% relative to a formulation based on the free acid.

Comparative crystal forms used in pharmaceutical development

Property	Mupirocin calcium dihydrate	Mupirocin free acid
Solid-state association	Two pseudomonic acid A carboxylate units per calcium ion	Single carboxylic acid unit
Theoretical water	3.3% w/w	Not applicable
Molecular mass	1074.3 g/mol	500.6 g/mol
Active-moiety mass fraction	0.932	1.000
Processing implication	Preferred when nonaqueous ointment or granulation stability is required; requires conversion factor in labeling	Reference for active-moiety calculations; may require more aggressive particle-size reduction
Compendial reference	USP Mupirocin Calcium monograph	USP Mupirocin monograph

In a high-shear granulator, the calcium dihydrate tends to form friable granules when purified water is sprayed at the impeller periphery; the free acid, by contrast, requires a higher binder solution volume because its contact angle with water is larger. The difference is amplified by the higher surface energy of the calcium salt after micronization. During wet massing in a 10-L high-shear granulator with an impeller speed of 250 rpm and a chopper speed of 3000 rpm, power draw rises from a dry-bed baseline of approximately 0.6 kW to a stabilized wet-bed value of 1.2 kW to 1.6 kW as granules densify. Operators using fixed-time granulation without impeller power trending often under-granulate the first development batch because the calcium salt requires a longer liquid absorption period before the power plateau is reached. End-point torque is therefore preferred to fixed time. For dry granulation, a roller compactor with roll pressure between 15 kN/cm and 25 kN/cm and roll speed from 5 rpm to 15 rpm produces ribbons that can be milled to a granule Dv50 of 250 µm to 500 µm for capsule filling. When a hard gelatin capsule formulation is prepared, the milled granules are blended with a disintegrant and lubricant in a bin blender operating at 15 rpm for 20 min. Lubricant overmixing is avoided because the calcium dihydrate has a high surface area after micronization and can accept excess magnesium stearate, delaying dissolution. Dissolution testing by USP <711> Apparatus II at 50 rpm in pH 6.8 phosphate buffer may show incomplete release because the low aqueous solubility of the calcium dihydrate limits sink conditions. Sodium dodecyl sulfate at 0.25% w/w to 1.0% w/w is commonly added to the dissolution medium to improve sink conditions, but the method must be justified under ICH Q2(R2) and USP <1092>. The release specification is then linked to the active-moiety correction factor, not simply to total calcium salt content. For extended-release tablet development, a hydrophilic matrix containing hypromellose at 10% w/w to 30% w/w is blended with the calcium dihydrate. Tableting is performed on a rotary press with main compression force between 8 kN and 18 kN for a 10-mm round flat-faced bevel-edge tooling. Ejection force is monitored because the fine calcium salt can increase die-wall friction when lubrication is insufficient; ejection force above 600 N is used as a process alarm. Compression profiles that exceed 18 kN can cause the hydrate lattice to lose surface water under adiabatic heating at high press speeds, leading to variable tablet hardness. A twin-screw extrusion feasibility batch on an 18-mm co-rotating twin-screw extruder with an L/D ratio of 25:1 may be used for continuous granulation of the calcium dihydrate when conventional high-shear equipment is unavailable. Barrel zone temperatures are held between 25 °C and 45 °C, and specific mechanical energy is monitored with a target below 0.35 kWh/kg. Published data for this specific API configuration is limited; therefore, the process is not considered fully predictable without small-scale torque rheometry. The calcium salt shows shear-thinning granule volume under continuous addition of water, and barrel pressure tends to rise when liquid-to-solids ratio exceeds 0.12. Stability of the pharma grade API is closely tied to water vapor exposure. At relative humidity above 60% RH, the micronized calcium dihydrate adsorbs surface water; this is not necessarily a change in the hydrate lattice but alters powder flow and assay on an as-is basis. Pre-drying at 40 °C for 2 h may be required before capsule filling when storage humidity exceeds this threshold. The calcium salt should not be combined with strong mineral acids or strong bases during aqueous granulation because the pseudomonic acid A ester and carboxylate functionalities are sensitive to extreme pH. Processing in aqueous media is therefore maintained between pH 4.5 and pH 7.5. The API is also protected from direct light; amber glass or opaque double polyethylene bags are used because the conjugated ester chromophore may undergo photodegradation.

Analytical release and process-monitoring matrix for Mupirocin Calcium Pharma Grade API

Control	Method or standard	Typical target
Identification	Infrared absorption and HPLC retention time against reference standard	Positive match
Assay on dried basis	USP Mupirocin Calcium monograph, HPLC	Compliant with monograph limits
Water content	USP <921> Karl Fischer	2.9% w/w to 3.6% w/w
Residual solvents	USP <467>, ICH Q3C	Class 3 solvents individual ≤ 5000 ppm
Elemental impurities	USP <232>, USP <233>, ICH Q3D	Route-specific permitted daily exposure values
Microbial limits	USP <61>, USP <62>	TAMC ≤ 100 CFU/g; TYMC ≤ 10 CFU/g for non-sterile grade
Bacterial endotoxins	USP <85>	≤ 0.25 EU/mg for injectable grade only
Particle size	ISO 13320:2020 laser diffraction	Dv90 ≤ 150 µm oral; Dv90 ≤ 25 µm injectable
Polymorphic identity	X-ray powder diffraction	Dihydrate pattern match
Sterility	USP <71>	Sterile for injectable grade

For granule production, a fluid-bed top-spray process is used after high-shear granulation to control residual moisture. Inlet air temperature is set at 45 °C to 55 °C, and drying continues until granule loss on drying is ≤ 2.0% w/w. Spray rate is adjusted so that the bed moisture does not exceed 12% during the wetting phase. End-point control by outlet air temperature alone is insufficient because the calcium dihydrate releases lattice water slowly; combined dew point and product temperature monitoring is more reproducible. Granules are sized through a 1.0-mm conical mill at 500 rpm before blending. This sizing step reduces agglomerate size and improves content uniformity as measured by USP <905>. An important manufacturing difference between the calcium dihydrate and other salt forms is the need to calibrate near-infrared moisture methods against Karl Fischer water, not against loss-on-drying alone. The calcium dihydrate has both surface moisture and lattice water, and a standard loss-on-drying method may over-report water if the temperature exceeds 60 °C. Therefore, Karl Fischer oven extraction at 110 °C is used to distinguish total water from surface water. This distinction matters in tablet granulation because surface water influences granule growth, while lattice water does not. The API is also characterized by its calcium content. Complexometric titration with edetate disodium may be used as a supplementary identity test, with a theoretical calcium fraction of approximately 3.7% w/w in the calcium dihydrate salt. The result is not used as a release assay because the HPLC method is more specific and stability-indicating. However, calcium content can identify incomplete salt formation when the material is reprocessed from the free acid. In capsule and tablet manufacture, the calcium dihydrate is typically not blended with strongly hygroscopic fillers such as sorbitol at high loadings because local water transfer may alter the dihydrate lattice at contact points. Microcrystalline cellulose, pregelatinized starch, and crospovidone are more commonly evaluated in development. Incompatibility with amine-based excipients is not reported as a major degradation pathway for mupirocin calcium, but the pH of the granulating fluid is controlled because the ester linkage and hemiacetal functionality of pseudomonic acid A are sensitive to extreme aqueous conditions. Therefore, wet granulation with citrate or phosphate buffers is occasionally used to maintain a pH between 5.0 and 6.5. For tablet and capsule dosage forms, the API is dispensed in a dedicated containment suite because the fermentation-derived material is a potent antibiotic and may cause sensitization in operators. Engineering controls include a downflow booth with an average face velocity of 0.5 m/s and high-efficiency particulate air filtration. Cleaning validation follows 21 CFR 211.67, with swab sampling and HPLC detection limits set below the lowest therapeutic dose expressed as mupirocin free acid. Batch records must distinguish the salt form from the free acid in the master formula; a conversion error at dispensing is a documented risk in multi-salt antibiotic campaigns. The solid oral grade is released against the current USP Mupirocin Calcium monograph and the relevant general chapters, but the fact that the product label includes tablet, capsule, granule, and injectable forms does not imply that each dosage form has a regulatory monograph or approved systemic indication. It indicates that the manufacturer grades the API for these downstream operations. A capsule or tablet formulation must be supported by product-specific dissolution, stability, and bioequivalence data; no universal release test substitutes for that development work. This limitation is especially relevant for injectable oral and systemic uses, where published clinical safety and efficacy data for mupirocin calcium is not established to the same extent as topical and intranasal products. In a typical batch record for a tablet process, the calcium dihydrate is passed through a 0.5-mm sieve prior to granulation to break soft lumps formed during storage. Pre-sieving is performed under nitrogen when open handling exceeds 4 h because residual oil-like impurities from fermentation can soften the powder at long open exposure. The API is then granulated, milled, blended, and compressed, with in-process assay on composite samples at the blender discharge and at the compression hopper. In-process assay samples are taken according to a stratified sampling plan, and the acceptance range for blend uniformity is 90.0% to 110.0% of the target label claim. These limits correspond to USP <905> uniformity of dosage units when the finished dosage form is evaluated. For injection development, a suspension formulation is prepared by dispersing the micronized calcium dihydrate in an aqueous vehicle containing a wetting agent and a tonicity-adjusting agent. The slurry is passed through a high-shear rotor-stator mixer at 10 000 rpm for 15 min before filling. Particle size after sterile filling is checked on retain samples by laser diffraction; an increase in Dv99 above 50 µm indicates aggregate formation and requires batch rejection. The suspension is not autoclaved unless terminal sterilization is specifically validated; the preferred method is aseptic processing of the pre-sterilized micronized powder. If gamma irradiation is used, the dose is maintained below 25 kGy because the ester functionality may degrade at higher doses. The exact irradiation limit for this API is not well established in public literature, so a dose-mapping study and post-irradiation assay are required batch-to-batch. Storage of the released API in double polyethylene bags inside fiber drums is common. Controlled room temperature is maintained at 20 °C to 25 °C, with excursions permitted between 15 °C and 30 °C under USP <659>. Retest dating is assigned after three months of accelerated stability at 40 °C and 75% RH for solid oral grade, and after six months at 25 °C and 60% RH for injectable grade. The stability-indicating HPLC method must resolve mupirocin calcium from its hydrolysis products, and all retest intervals are based on the first point where any related substance exceeds the pharmacopeial reporting threshold.